Additionally, complement system inhibitors, including C5a receptor (C5aR) antagonist, C5a monoclonal antibodies, C1 inhibitor, cobra venom factor (CVF), and soluble complement receptor type 1 (sCR1), have been shown to be effective in attenuating liver IR injury [94]. Here, C5AR1 is linked to digestive system neoplasm.